Alessia Tomberli

Dr. Alessia Tomberli


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
MZmattia zampieri
mattia zampieri
AAAlessia Argirò
Alessia Argirò
AMAlberto Marchi
Alberto Marchi
MBMartina Berteotti
Martina Berteotti
MTMattia Targetti
Mattia Targetti
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto

Verified
Journal Article
Open access
PDF file
NMNiccolò Maurizi
Niccolò Maurizi
CCChiara Chiriatti
Chiara Chiriatti
CFCarlo Fumagalli
Carlo Fumagalli
MTMattia Targetti
Mattia Targetti
SPSilvia Passantino
Silvia Passantino
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Background: Although disopyramide has been widely used to reduce left ventricular outflow obstruction (LVOTO) and to improve symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM), its use in real world as well as patient characteristics associated with a positive treatment response are still unclear. Methods: From 1980 to 2021, 1527 patients with HCM were evaluated and 372 (23%) had a LVOTO with active follow-up. The efficacy and safety of disopyramide were assessed systematically during 12 months (2-, 6-, and 12-month visits). Responders were patients with a final NYHA = I and a LVOTO < 30 mmHg; incomplete responders were those patients with NYHA > I and a LVOTO < 30 mmHg; and non-responders were symptomatic patients with no change in functional class NYHA and a LVOT gradient > 30 mmHg. Results: Two-hundred-fifty-four (66%) patients were in functional class NYHA I/II and 118 (34%) in NYHA III/IV. A total of 118/372 (32%, 55 ± 16 years) underwent disopyramide therapy. Twenty-eight (24%) patients responded to therapy, 39 (33%) were incomplete responders, and 51 (43%) did not respond. Responder were mainly patients in functional NYHA class I/II (24/28, 86%), whereas incomplete responders and non-responders were more often in functional NYHA class III/IV (50/54 (93%)). An independent predictor of response to disopyramide treatment was the presence of NYHA I/II at the initiation of therapy (HR 1.5 (95% CI 1.1–4.5), p = 0.03). No major life-threatening arrhythmic events or syncope occurred, despite 19 (16%) patients showing reduced QTc from baseline, 19 (16%) having no difference, while 80 (69%) patients had prolonged QTc interval. Thirty-one (26%) patients experienced side effects, in particular, 29 of the anticholinergic type. Conclusions: Disopyramide was underused in oHCM but effective in reducing LVOTO gradients and symptoms in slightly symptomatic patients with less severe disease phenotype with a safe pro-arrhythmic profile.

24 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FGFrancesca Girolami
Francesca Girolami
AGAlessia Gozzini
Alessia Gozzini
Eszter Dalma PalinkasEszter Dalma Palinkas
Eszter Dalma Palinkas
ABAdelaide Ballerini
Adelaide Ballerini
ATAlessia Tomberli
Alessia Tomberli
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Genetic counselling and genetic testing in hypertrophic cardiomyopathy (HCM) represent an integral part of the diagnostic algorithm to confirm the diagnosis, distinguish it from phenocopies, and suggest tailored therapeutic intervention strategies. Additionally, they enable cascade genetic testing in the family. With the implementation of Next Generation Sequencing technologies (NGS), the interpretation of genetic data has become more complex. In this regard, cardiologists play a central role, aiding geneticists to correctly evaluate the pathogenicity of the identified genetic alterations. In the ideal setting, geneticists and cardiologists must work side by side to diagnose HCM as well as convey the correct information to patients in response to their many questions and concerns. After a brief overview of the role of genetics in the diagnosis of HCM, we present and discuss the frequently asked questions by HCM patients throughout our 20-year genetic counselling experience. Appropriate communication between the team and the families is key to the goal of delivering the full potential of genetic testing to our patients.

28 January 2020 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
CFCarlo Fumagalli
Carlo Fumagalli
MGMaria Grazia De Gregorio
Maria Grazia De Gregorio
MZmattia zampieri
mattia zampieri
EFElisa Fedele
Elisa Fedele
ATAlessia Tomberli
Alessia Tomberli
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto